Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) often develop resistance to current standard third-generation EGFR tyrosine kinase inhibitors (TKIs); no targeted treatments are approved in the osimertinib-relapsed setting. In this open-label, dose-esc...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Byoung Chul, Kim, Dong-Wan, Spira, Alexander I., Gomez, Jorge E., Haura, Eric B., Kim, Sang-We, Sanborn, Rachel E., Cho, Eun Kyung, Lee, Ki Hyeong, Minchom, Anna, Lee, Jong-Seok, Han, Ji-Youn, Nagasaka, Misako, Sabari, Joshua K., Ou, Sai-Hong Ignatius, Lorenzini, Patricia, Bauml, Joshua M., Curtin, Joshua C., Roshak, Amy, Gao, Grace, Xie, John, Thayu, Meena, Knoblauch, Roland E., Park, Keunchil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579096/
https://www.ncbi.nlm.nih.gov/pubmed/37710001
http://dx.doi.org/10.1038/s41591-023-02554-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579096/
https://www.ncbi.nlm.nih.gov/pubmed/37710001
http://dx.doi.org/10.1038/s41591-023-02554-7

Ejemplares similares